## In the Claims

Please amend the claims as follows:

- 1. (Original) A surface glycoprotein comprising the following features: (a) it is GPI-anchored on the cell surface; (b) it can be removed from the cell membrane by treatment with PI-PLC; and (c) its GPI-anchor is characterized by a non-acetylated inositol ring and diacyl glycerol as lipid tail of the anchor.
- 2. (Original) The surface glycoprotein of claim 1 which is the surface glycoprotein ACA characterized by the following additional features: (d) it has an isoelectric point of pH 5.5; (e) it is present on progenitor cells, granulocytes, monocytes, B-cells (but not T-cells), melanocytes, and other cells; and (f) it is preferentially expressed during cell division and in tumor cells; or a salt, functional derivative or active fraction thereof.
- 3. (Original) The surface glycoprotein ACA of claim 2, obtainable from human blood by (a) isolating and lysing cells; (b) isolating, disrupting and pelleting the hemoglobin free membrane of said cells; (c) repeated salting out of the resuspended membranes with ammonium sulfate (70%; 40% saturation); (d) subjecting the proteins precipitated in step (c) to preparative SDS-PAGE under reducing conditions; and (e) isolating the gel band of the protein.
- 4. (Previously presented) The surface glycoprotein ACA of claim 3 having a molecular weight of about 65 or 68 kD when analyzed by SDS PAGE under reducing conditions.
- 5. (Currently amended) The surface glycoprotein ACA of claim 2 which contains at least one of the following amino acid sequences:
- (a) D-L-V-P-L-E-D-K-V-T-I-L-G-M-T-A; (SEQ ID NO: 1)
- (b) K-L-A-L-S-A-D-D-P-G-F-H-N-F-S-H-Q-R-Q-T; (SEQ ID NO: 2)
- (c) D-Q-Q-T-T-S-H-S-S; (SEQ ID NO: 3)
- (d) V-L-E-I-M-L-P; (SEQ ID NO: 4)
- (e) F-Q-D-E-S-E-A-N-K; (SEQ ID NO: 5)
- (f) M-K-Y-V-N-F-K-F-Y-F; (SEQ ID NO: 6)
- (g) N-L-D-F-M-T-W-G-V-T-K-V-T-Y-I-G-Q-P-T-G-G; (SEQ ID NO: 7)
- (h) L-L-M-D-N-N-E-A-V-H; (SEQ ID NO: 8)

- (i) F-D-Q-A-W-A-D-T-A-H-T-W; (SEQ ID NO: 9)
- (j) K-L-D-D-I-Q-K-D-M-Y-S-Q-Q-D-T (SEQ ID NO: 10); or
- (k) G-V-W-I-M-K-N-Q-I-T. (SEQ ID NO: 11)
- 6. (Previously presented) The surface glycoprotein ACA of claim 2 which is isolated from blood cells.
- 7. (Original) A process for the isolation of a surface glycoprotein ACA which comprises:
- a) isolating and lysing cells from human blood;
- (b) isolating, disrupting and pelleting the hemoglobin free membrane of said cells;
- (c) repeated salting out of the resuspended membranes with ammonium sulfate (70%; 40% saturation);
- (d) subjecting the proteins precipitated in step (c) to preparative SDS-PAGE under reducing conditions; and
- (e) isolating the gel band of a 65 or 68 kD protein.
- 8. (Original) The surface glycoprotein ACA produced by the process of claim 7.
- 9. (Previously presented) The surface glycoprotein of claim 5 which is a recombinant protein.
- 10. (Original) The surface glycoprotein of claim 9 which is produced in a mammalian cell.
- 11. (Currently amended) A nucleic acid molecule comprising a nucleotide sequence encoding the surface glycoprotein ACA or a functional derivative or fragment thereof of claim 2, wherein said surface glycoprotein ACA contains at least one of the following amino acid sequences:
- (a) D-L-V-P-L-E-D-K-V-T-I-L-G-M-T-A; (SEQ ID NO: 1)
- (b) K-L-A-L-S-A-D-D-P-G-F-H-N-F-S-H-Q-R-Q-T; (SEQ ID NO: 2)
- (c) D-Q-Q-T-T-S-H-S-S; (SEQ ID NO: 3)
- (d) V-L-E-I-M-L-P; (SEQ ID NO: 4)
- (e) F-Q-D-E-S-E-A-N-K; (SEQ ID NO: 5)
- (f) M-K-Y-V-N-F-K-F-Y-F; (SEQ ID NO: 6)
- (g) N-L-D-F-M-T-W-G-V-T-K-V-T-Y-I-G-Q-P-T-G-G; (SEQ ID NO: 7)
- (h) L-L-M-D-N-N-E-A-V-H; (SEQ ID NO: 8)
- (i) F-D-Q-A-W-A-D-T-A-H-T-W; (SEQ ID NO: 9)

- (j) K-L-D-D-I-Q-K-D-M-Y-S-Q-Q-D-T; (SEQ ID NO: 10) or
- (k) G-V-W-I-M-K-N-Q-I-T. (SEQ ID NO: 11)
- 12. (Original) The nucleic acid molecule of claim 11 wherein the nucleotide sequence is a genomic DNA sequence or a CDNA sequence.
- 13. (Previously presented) An expression vector comprising the nucleic acid molecule of claim 11.
- 14. (Original) A host cell transformed with the expression vector of claim 13.
- 15. (Original) The host cell of claim 14 which is a mammalian host cell.
- 16. (Previously presented) A process for producing a surface glycoprotein ACA comprising the steps of: (a) culturing a transformed host cell according to claim 14 in a suitable culture medium; and (b) isolating the protein form the cells or the culture medium.
- 17. (Previously presented) An antibody to the surface glycoprotein according to claim 5.
- 18. (Original) The antibody of claim 17 which is a monoclonal antibody.
- 19. (Previously presented) A method for the diagnosis of a tumor associated with overexpression of ACA or a predisposition for such a tumor which comprises
- (a) contacting a target sample with a compound which is capable of specifically binding (i) to the surface glycoprotein ACA according to claim 4 determining the level of ACA; and
- (b) comparing the level of ACA protein of the sample determined by use of the compound of step
- (a) with a control sample obtained from a healthy individual, wherein an elevated level of the surface glycoprotein ACA is indicative for a tumor or a predisposition for such a tumor.
- 20. (Previously presented) The method of claim 19, wherein the compound is an antibody.
- 21. (Original) A pharmaceutical composition containing a compound capable of reducing or eliminating (a) the expression of the nucleic acid sequence encoding the surface glycoprotein ACA and/or (b) the biological activity of ACA.

## 22. Cancelled

- 23. (Previously presented) The method of claim 19, wherein the cancer is a melanoma, leukemia, renal cancer, lung cancer, breast cancer, colon cancer, gastric cancer, or any other form of cancer.
- 24. (Previously presented) A kit containing the antibody of claim 17.